Skip to main content

Table 1 Attributes and attribute levels presented for hypothetical treatments choice set scenarios

From: Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists

Therapeutic attributes

Levels

Clinical effects (average): average years of delay in progression to moderate stage of Alzheimer’s disease, compared to standard of care

• 1.5 years

• 2.5 years

• 3.5 years

Clinical effects (variation): distribution in the magnitude of clinical effects achieved among patients

• Narrow

• Wide

Biomarker response (amyloid clearance): proportion of patients achieving amyloid negativity on PET scan at 1 year

• 3 in 10 patients (30%)

• 7 in 10 patients (70%)

Adverse events (symptomatic ARIA-E): proportion of patients developing symptomatic ARIA-E during treatment

• 1 in 100 patients (1%)

• 1 in 20 patients (5%)

• 1 in 4 patients (25%)

Treatment duration: total length of entire treatment course

• 1 year

• 3 years

• 5 years

Treatment titration (at initiation): requirement to adjust dosage of medication when first starting treatment

• Does not require dosage titration

• Requires dosage titration (typically for 3–8 months)

Treatment administration: route and frequency of medication administration

• Intravenous every 2 weeks

• Intravenous every 4 weeks

• Subcutaneous every 2 weeks

  1. ARIA-E Amyloid-related imaging abnormalities-edema